Christi Shaw Biography and Net Worth

Christi Shaw serves as Chief Executive Officer of Kite, Gilead's cell therapy company. Based in Santa Monica, California, Kite is pursuing the ambitious goal of a cure for cancer with industry-leading pipeline and manufacturing capabilities. In her role, Christi is responsible for all cell therapy operations around the world.

Before joining Gilead in 2019, Christi held senior executive positions at Eli Lilly & Co. and Novartis Corp. Her leadership has spanned a broad range of therapeutic areas, including oncology.

Christi holds a bachelor's degree in business administration from Iowa State University and an MBA from the University of Wisconsin.

In 2016, she founded the More Moments More Memories Foundation, which assists patients with cancer and their families. Christi currently serves on the board of directors of the Biotechnology Innovation Organization, Avantor and the Healthcare Women's Business Association.

What is Christi Shaw's net worth?: The estimated net worth of Christi Shaw is at least $9.31 million as of December 11th, 2020. Ms. Shaw owns 11,319 shares of Eli Lilly and Company stock worth more than $9,305,757 as of March 28th. This net worth estimate does not reflect any other assets that Ms. Shaw may own. Learn More about Christi Shaw's net worth.
How do I contact Christi Shaw?: The corporate mailing address for Ms. Shaw and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at johnson_philip_l@lilly.com. Learn More on Christi Shaw's contact information.
Has Christi Shaw been buying or selling shares of Eli Lilly and Company?: Christi Shaw has not been actively trading shares of Eli Lilly and Company in the last ninety days. Most recently, Christi Shaw sold 7,577 shares of the business's stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $117.14, for a transaction totalling $887,569.78. Following the completion of the sale, the senior vice president now directly owns 500 shares of the company's stock, valued at $58,570. Learn More on Christi Shaw's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, insiders at the sold shares 21 times. They sold a total of 1,216,604 shares worth more than $1,068,382,597.80. The most recent insider tranaction occured on March, 13th when CAO Donald A Zakrowski sold 1,000 shares worth more than $818,240.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 3/13/2025.

Christi Shaw Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/3/2019	Sell	7,577	$117.14	$887,569.78	500
5/29/2018	Sell	8,426	$82.10	$691,774.60

Christi Shaw Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $822.14

$815.29

$826.77

50 Day Range

MA: $842.43

$726.24

$930.22

2 Week Range

Now: $822.14

$711.40

$972.53

Volume

2,126,892 shs

Average Volume

3,153,206 shs

Market Capitalization

$779.52 billion

P/E Ratio

70.21

Dividend Yield

0.70%

Beta

0.34